Bavarian Nordic — November 2019
-
Financial results for the first nine months of 2019
Revenue DKK 29.8 million / USD 4.4 million (DKK 24.9 million / USD 3.9 million in the first nine months of 2018).
Net operating expenses DKK 431.5 million / USD 62.9 million (DKK 330.6 million / USD 51.3 million in the first nine months of 2018).
Net operating result DKK –402.1 million / USD –58.7 million (DKK 797.5 million / USD 123.8 million in the first nine months of 2018).
Cash including marketable securities amounted to DKK 1,543.2 milli -
Ny Zealand Pharma-direktør: Endelig forstår markedet vores værdi - vi får stor opmærksomhed fra amerikanske investorer:
-
Ja, exitnu...det går godt, og jeg tænker, at jeg ihverfald tager de 3 år med der tales om. 400+ virker ikke så langt væk og hvem ved hvor tålmodigheden ender. Til evt. andre læsere. De 400+ står som et mål exitnu og undertegnede har talt om længe. Da hollænderne kom ind talte de i virkeligheden om 500 og dertil skal man så lægge de nye tilkøb. Men altså det er en langvarig affære, for mit vedkommende 4 år indtil videre. God aften.
-
-
Bava: godt at se at de fortsætter med at forske indenfor nye områder https://www.ncbi.nlm.nih.gov/pubmed/31718901
-
Bryan Garnier hæver target på Zeal til 217 fra 209. Af en eller anden grund fastholder de købsanbefalingen. Kursen ligger jo ellers et stykke over de 217.
-
Test
-
danske hæver target på zeal
til 315 -
What is the NASDAQ Stock Exchange?
View a list of the top-rated stocks to buy listed on the NASDAQ Stock Exchange (NASDAQ) at MarketBeat.
MarketBeat (www.marketbeat.com)
-
Her er hvad Jefferies skriver om Zeal: Jefferies analyst Peter Welford downgraded Zealand Pharma to Hold from Buy with a price target of DKK235.00, up from DKK185.00. His recent survey of U.S. physicians and recent script trends drive confidence that the launch of ready-to-use glucagon rescue devices will expand the market, but commercial execution is now a risk given the plan to self-commercialize lead asset dasiglucagon HypoPal device as likely third to market, Welford tells investors.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind